Skip to main content

Table 2 Endpoints from study investigating EPA/placebo vs. EPA/celecoxib by Cerchietti et al [30]

From: A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), Resistance Training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients - ACCeRT Study

  Fish oil/placebo Fish oil/celecoxib pvalues
Grip strength 1.16 (0.3) 3.12 (0.95)* P = 0.002
Body weight (Kg) -1.4 (0.84) 1.5 (1.2)* P = 0.05
LBM (Kg) -0.6 (0.67) 0.4 (0.6) NS
Fat Mass (Kg) -0.6 (0.8) 1.2 (0.64) NS
  1. LBM = Lean body mass. Data are recorded mean with SE in parentheses.*P < 0.02 compared to their respective baseline value.